The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Emory receives $400 million pledge from Woodruff Foundation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

A $400 million pledge to Emory University from the Robert W. Woodruff Foundation will be used to construct a Winship Cancer Institute Tower in Midtown Atlanta and a new Health Sciences Research Building on Emory’s Druid Hills campus.

The Winship Cancer Institute Tower in Midtown will house a full range of outpatient cancer services.

The new Health Sciences Research Building on Emory’s Druid Hills campus, a laboratory-focused facility, will house faculty and staff who are charged with developing a pipeline of cures, interventions, and prevention methods, all aimed at improving the health of patients.

Research teams will partner with Emory colleagues to target five emerging priorities in 21st century medicine: cancer; brain health; heart and vascular health; immunology and infectious diseases; and radiology, biomedical engineering, and imaging sciences. Emory’s partnerships also include Children’s Healthcare of Atlanta.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
By Claire Marie Porter
Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account